Insights from a Long-Term Follow-Up Evaluation of Early Breast Cancer Outcomes by Tumor Subtype.

Oncology Research and Treatment
Elisa ZanardiAlessandra Rubagotti

Abstract

Our understanding of the granularity of breast cancer (BC) clinical outcomes by biologic subtype may be impaired by limited study follow-up times. We evaluated the impact of modern immunohistochemistry (IHC)-based BC subtypes on long-term mortality. We used a cohort of 200 women diagnosed with stage I-III BC in the period 1985-1990. Surgical samples underwent centralized pathology review. Multivariate models assessed associations of subtype with overall survival (OS) and BC-related survival (BCRS). 42.0% women had luminal A-like, 32.5% luminal B-like/human epidermal growth factor receptor (HER)2-negative, 8.5% had HER2-positive, and 17.0% had triple-negative BC. 53.0% had tumor size (T) >2 cm and 47.5% had a positive nodal status (N). Over 18.7 years of median follow-up (range 0.3-32.0 years),140 deaths were recorded (75 BC-related). Median OS was longest for patients with luminal A-like tumors (21.2 years; 95% confidence interval [CI] 17.4-24.9]). The luminal B-like/HER2-negative subtype was significantly associated with worse BCRS (adjusted hazard ratio [HR] = 1.86; 95% CI 1.09-3.16). After multivariable analysis, T >2 cm (HR [vs. ≤2 cm] = 1.71 [95% CI 1.03-2.84]) and positive N (HR [vs. negative] = 2.19 [95% CI 1.03-4.65]) i...Continue Reading

References

Aug 1, 1991·Breast Cancer Research and Treatment·L BergmanF E van Leeuwen
Mar 1, 1989·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P R RosenS Hellman
Jul 24, 1987·JAMA : the Journal of the American Medical Association·T Wetle
Oct 1, 1994·Cancer·E L TrimbleM A Friedman
Jun 5, 1996·Journal of the National Cancer Institute·R Ballard-BarbashL G Kessler
Aug 26, 1998·British Journal of Cancer·R L JansenH F Hillen
Aug 30, 2000·Nature·C M PerouD Botstein
Mar 17, 2001·JAMA : the Journal of the American Medical Association·R YancikJ W Yates
Jun 28, 2003·Proceedings of the National Academy of Sciences of the United States of America·Therese SorlieDavid Botstein
Dec 23, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·F BoccardoA Rubagotti
Oct 21, 2005·The New England Journal of Medicine·Martine J Piccart-GebhartUNKNOWN Herceptin Adjuvant (HERA) Trial Study Team
Oct 28, 2005·The New England Journal of Medicine·Donald A BerryUNKNOWN Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators
Jun 8, 2006·JAMA : the Journal of the American Medical Association·Lisa A CareyRobert C Millikan
Oct 13, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H F KenneckeK A Gelmon
Jul 20, 2007·Annals of Surgical Oncology·Timothy KennedyDavid P Winchester
Nov 5, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Giuseppe VialeUNKNOWN Breast International Group Trial 1-98
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joel S ParkerPhilip S Bernard
Feb 11, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Judith HughCharles Vogel
May 14, 2009·Journal of the National Cancer Institute·Maggie C U CheangTorsten O Nielsen
Nov 4, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ana M Gonzalez-AnguloGabriel N Hortobagyi
May 26, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hagen KenneckeKaren Gelmon
Sep 15, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Torsten O NielsenMatthew J Ellis
Jun 29, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Nov 2, 2011·The Breast : Official Journal of the European Society of Mastology·Marco ColleoniSilvia Dellapasqua
Nov 19, 2011·Breast Cancer Research and Treatment·Pamela GuglielminiFrancesco Boccardo
Nov 23, 2012·The New England Journal of Medicine·Archie Bleyer, H Gilbert Welch
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Aleix PratCharles M Perou
Aug 7, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A GoldhirschUNKNOWN Panel members
Oct 9, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffUNKNOWN College of American Pathologists
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisRachel A Freedman
Apr 24, 2014·Breast Cancer Research and Treatment·Rachel A FreedmanNancy L Keating
Jun 4, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ines Vaz-LuisNancy U Lin
May 6, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A S CoatesUNKNOWN Panel Members
Aug 1, 2015·International Journal of Molecular Sciences·Pier Vitale NuzzoFrancesco Boccardo
Aug 9, 2015·The Breast : Official Journal of the European Society of Mastology·Aleix PratMontserrat Muñoz
Sep 1, 2015·The Breast : Official Journal of the European Society of Mastology·Christopher D HartAngelo Di Leo
Apr 25, 2016·Breast Cancer Research and Treatment·E S BergenR Bartsch
Apr 28, 2016·The Breast : Official Journal of the European Society of Mastology·Serena Di CosimoValter Torri

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Related Papers

The Breast : Official Journal of the European Society of Mastology
Silvia M EssBeat Thürlimann
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
Carlos A CastanedaEva Ciruelos
© 2022 Meta ULC. All rights reserved